Posters
« Back
Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
EP25778
Poster Title: Improved T Cell Activation Bioassays for Development of Bispecific Antibodies and Engineered T Cell Immunotherapies
Submitted on 15 May 2017
Author(s): Pete Stecha, Denise Garvin, Jim Hartnett, Frank Fan, Mei Cong and Zhi-jie Jey Cheng
Affiliations: Promega Corporation, 2800 Woods Hollow Rd, Madison, WI 53711
Poster Views: 2,605
View poster »


Poster Information
Abstract: Immunotherapy aims to boost a patient’s own immune system to fight disease. In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening or engineering T cell responses have emerged as promising approaches for the treatment of cancer and autoimmune disease.

Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.

Specifically, we developed two bioluminescent reporter-based bioassays to measure T cell activation via CD3 (NFAT-RE) or CD3 + CD28 (IL-2 promoter). These
Summary: Here we describe a platform of T cell activation bioassays for the development of CD3 bispecific antibodies and engineered T cell immunotherapies.References: Corresponding author: richard.somberg@promega.comReport abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Transporters
Creative BioMart

Superoxide Dismutase
Creative Enzymes

a comparison of dispense performance of manual pipetting versus automated pipetting for assay development
Anne F. Hammerstein, David J. Onley, Joby Jenkins, Paul G. Wylie, Sarah Payne

Depressive mood disorders in relation to T cell abnormalities in a cohort of common variable immune deficiency patients
Olivia Manusama, Hemmo Drexhage, Martin van Hagen, Maksym Ahiyevets, Tom Birkenhäger, Virgil Dalm

Can HIV/AIDS transmit by food?
Shahad sarmad and muhand khalid under the supervision of Dr reem Abu Assi